Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL)

Blood (2024) 144 (Supplement 1): 4362.

https://doi.org/10.1182/blood-2024-203004

Published: 2024

Journal Articles

TP53 , CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial

Blood (2024) 144 (Supplement 1): 1577.

https://doi.org/10.1182/blood-2024-198076

Published: 2024

Journal Articles

Longitudinal Monitoring of Circulating Tumor DNA to Predict Survival in Newly Diagnosed Peripheral T-Cell Lymphoma Patients

Blood (2024) 144 (Supplement 1): 1580.

https://doi.org/10.1182/blood-2024-201391

Published: 2024

Journal Articles

Prognostic Impact of Pre-Treatment Cell-Free DNA Concentration in Newly Diagnosed Peripheral T-Cell Lymphomas

Eugenio Fardella, Giada Zanirato, Martina Magni, Nicole Caldarelli, Annalisa Chiappella, Anna Dodero, Silva Ljevar, Lorella Orsucci, Alessandro Re, Sara Usai, Vittorio Stefoni, Claudia Castellino, Francesca Gaia Rossi, Antonio Pinto, Cristiana Carniti, Paolo Corradini

Blood (2023) 142 (Supplement 1): 1695.

https://doi.org/10.1182/blood-2023-189215

Published: 2023

Journal Articles

Rituximab and Lenalidomide (R 2 ) Vs Rituximab Alone As Maintenance Treatment after Chemoimmunotherapy for Elderly Patients with Relapsed/Refractory Follicular Lymphoma (FL): Final Analysis of Renoir Phase III Study of the Fondazione Italiana Linfomi (FIL)

Blood (2023) 142 (Supplement 1): 982.

https://doi.org/10.1182/blood-2023-174901

Published: 2023

Journal Articles

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Older Patients with Mantle Cell Lymphoma: A Phase 2 Study By the Fondazione Italiana Linfomi (FIL)

Blood (2023) 142 (Supplement 1): 737.

https://doi.org/10.1182/blood-2023-179169

Published: 2023

Journal Articles

The Addition of Romidepsin to CHOEP and High-Dose Chemotherapy Plus Stem Cell Transplantation Did Not Ameliorate the Outcome of Untreated Angioimmunoblastic T-Cell or Follicular T-Helper Lymphoma: Subgroup Analysis of Phase II FIL-PTCL13 Study

Blood (2022) 140 (Supplement 1): 6538–6539.

https://doi.org/10.1182/blood-2022-163824

Published: 2022

Journal Articles

Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma

Blood (2022) 140 (12): 1378–1389.

https://doi.org/10.1182/blood.2021014270

Published: 2022

Includes: Supplemental data

Journal Articles

Adding Romidepsin to CHOEP in First Line Treatment of Peripheral T-Cell Lymphomas Does Not Improve the Response Rate: Final Analysis of Phase II PTCL13 Study

Blood (2021) 138 (Supplement 1): 134.

https://doi.org/10.1182/blood-2021-153680

Published: 2021

Journal Articles

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Elderly Patients with Mantle Cell Lymphoma

Blood (2021) 138 (Supplement 1): 2427.

https://doi.org/10.1182/blood-2021-145421

Published: 2021

Journal Articles

Comprehensive Minimal Residual Disease (MRD) Analysis of the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial for Younger Patients with Mantle Cell Lymphoma: A Kinetic Model Ensures a More Refined Risk Stratification

Blood (2018) 132 (Supplement 1): 920.

https://doi.org/10.1182/blood-2018-99-114442

Published: 2018

Journal Articles

LONG-TERM Outcome of a Fondazione Italiana Linfomi Study Comparing Short Rituximab Maintenance Vs Observation after Brief First-LINE R-FND Chemoimmunotherapy Followed By Rituximab Consolidation in Elderly Patients with Advanced Follicular Lymphoma (FL)

Blood (2015) 126 (23): 3985.

https://doi.org/10.1182/blood.V126.23.3985.3985

Published: 2015

Journal Articles

Prolonged Survival Of Poor Risk Follicular Lymphoma Patients Following Primary Treatment With Rituximab-Supplemented CHOP Or HDS With Autograft: Long-Term Results Of The Multicenter Randomized GITMO/FIL Trial

Blood (2013) 122 (21): 551.

https://doi.org/10.1182/blood.V122.21.551.551

Published: 2013

Journal Articles

Radioimmunotherapy (RIT) with 90 y-Ibritumomab Tiuxetan (Zevalin) in Relapsed or Refractory Aggressive Lymphoma Previously Treated with Rituximab Containing Regimens

Barbara Botto, Marilena Bellò, Annalisa Chiappella, Roberto Passera, Giulia Benevolo, Carola Boccomini, Maria Giuseppina Cabras, Claudia Castellino, Giuseppe Fioritoni, Chiara Frairia, Roberto Freilone, Maurizio Martelli, Lorella Orsucci, Patrizia Pregno, Paola Scapoli, Anna Tonso, Umberto Ricardi, Giovanni Bisi, Umberto Vitolo

Blood (2008) 112 (11): 5014.

https://doi.org/10.1182/blood.V112.11.5014.5014

Published: 2008

Journal Articles

Patients with aaIPI 2-3 Diffuse Large B-Cell Lymphoma Achieve 75% Long-Term Survival Following First-Line Rituximab-Supplemented High-Dose Sequential Chemotherapy and Autograft: Final Results of the Prospective Phase II GITIL ( Gruppo Italiano Terapie Innovative nei Linfomi ) Trial.

Corrado Tarella, MD, Manuela Zanni, MD, Massimo Di Nicola, MD, Caterina Patti, MD, Claudia Castellino, MD, Roberto Crocchiolo, MD, Valerio Zoli, MD, Daniele Caracciolo, MD, Michele Magni, MD, Mario Boccadoro, MD, Fabio Ciceri, MD, Paolo Corradini, MD, Andrea Gallamini, MD, Ignazio Majolino, MD, Salvo Mirto, MD, Alessandro M. Gianni, MD

Blood (2007) 110 (11): 1889.

https://doi.org/10.1182/blood.V110.11.1889.1889

Published: 2007

Journal Articles

High-Dose Sequential Chemotherapy (HDS) Followed by Autologous Stem Cell Transplantation (ASCT) in Relapsing/Refractory Hodgkin Lymphoma (HL): Long-Term Results.

Andrea Gallamini, Claudia Castellino, Simonetta Viviani, Andrea Rossi, Atto Billio, Alessandro Mistretta, Marco Sorio, Angela Gueli, Alessandro Rambaldi, Sergio Cortelazzo, Caterina Patti, Fabio Benedetti, PierFederico Torchio, Alessandro M. Gianni, Corrado Tarella

Blood (2007) 110 (11): 5118.

https://doi.org/10.1182/blood.V110.11.5118.5118

Published: 2007

Journal Articles

Radioimmunotherapy (RIT) with 90 Y-Ibritumomab Tiuxetan (Zevalin) for the Treatment of Relapsed or Resistant Aggressive Diffuse Large B-Cell Lymphoma (DLBCL) Heavily Pretreated with Rituximab + Chemotherapy: A GIMURELL Experience.

Barbara Botto, Marilena Bellò, Giulia Benevolo, Maria Giuseppina Cabras, Claudia Castellino, Annalisa Chiappella, Giuseppe Fioritoni, Roberto Freilone, Maurizio Martelli, Lorella Orsucci, Patrizia Pregno, Paola Scapoli, Anna Tonso, Giovanni Bisi, Umberto Vitolo, Eugenio Gallo

Blood (2007) 110 (11): 4478.

https://doi.org/10.1182/blood.V110.11.4478.4478

Published: 2007

Journal Articles

Hyperchidam Verona897 Regimen Is Effective in Treatment of Advanced Peripheral T Cell Lymphoma (PTCL): The GITIL Experience in 33 Cases.

Giuseppe Todeschini, MD, Paolo Corradini, MD, Sergio Cortelazzo, MD, Alessandro Rambaldi, MD, Andrea Gallamini, MD, Fabio Benedetti, MD, Andres Ferreri, MD, Attilio Olivieri, MD, Cristina Tecchio, MD, Massimiliano Bonifacio, MD, Niccolo Frungillo, MD, Claudia Castellino, MD, Andrea Rossi, MD, Chandrakala Toldo, MD, Roberto Crocchiolo, MD, Immacolata Attolico, MD, Giovanni Pizzolo, MD

Blood (2007) 110 (11): 4465.

https://doi.org/10.1182/blood.V110.11.4465.4465

Published: 2007

Journal Articles

High CR Rate and Prolonged EFS in aaIPI 2 – 3 Diffuse Large B-Cell Lymphoma Following High-Dose Sequential Chemotherapy and In Vivo Rituximab-Purged Stem Cell Autografting (R-HDS Regimen): Results of a Prospective Phase II Multicenter Study Sponsored by GITIL ( Gruppo Italiano Terapie Innovative nei Linfomi ).

Corrado Tarella, MD, Manuela Zanni, MD, Massimo Di Nicola, MD, Caterina Patti, MD, Claudia Castellino, MD, Alessandra Pescarollo, MD, Valerio Zoli, MD, Daniele Caracciolo, MD, Marco Ladetto, MD, Michele Magni, MD, Liliana Devizzi, MD, Mario Boccadoro, MD, Marco Bregni, MD, Paolo Corradini, MD, Andrea Gallamini, MD, Ignazio Majolino, MD, Salvo Mirto, MD, Alessandro M. Gianni, MD

Blood (2005) 106 (11): 2068.

https://doi.org/10.1182/blood.V106.11.2068.2068

Published: 2005

Journal Articles

Telomere Length Has Prognostic Impact in B-Cell Chronic Lymphocytic Leukemia (B-CLL).

Irene Ricca, MD, Daniela Drandi, PhD, Alberto Rocci, MD, Mara Compagno, PhD, Roberto Francese, PhD, Barbara Mantoan, PhD, Claudia Castellino, MD, Francesca Ficara, MD, Sonia Vallet, MDD, Maria Dell’Aquila, PhD, Loredana Santo, MD, Daniele Caracciolo, MD, Luciana Bergui, MD, Andrea Gallamini, MD, Mario Bazzan, MD, Carlo Marinone, MD, Mario Boccadoro, MD, Corrado Tarella, MD, Marco Ladetto, MD

Blood (2004) 104 (11): 4768.

https://doi.org/10.1182/blood.V104.11.4768.4768

Published: 2004

NARROW

Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL)

TP53 , CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial

Longitudinal Monitoring of Circulating Tumor DNA to Predict Survival in Newly Diagnosed Peripheral T-Cell Lymphoma Patients

Prognostic Impact of Pre-Treatment Cell-Free DNA Concentration in Newly Diagnosed Peripheral T-Cell Lymphomas

Rituximab and Lenalidomide (R 2 ) Vs Rituximab Alone As Maintenance Treatment after Chemoimmunotherapy for Elderly Patients with Relapsed/Refractory Follicular Lymphoma (FL): Final Analysis of Renoir Phase III Study of the Fondazione Italiana Linfomi (FIL)

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Older Patients with Mantle Cell Lymphoma: A Phase 2 Study By the Fondazione Italiana Linfomi (FIL)

The Addition of Romidepsin to CHOEP and High-Dose Chemotherapy Plus Stem Cell Transplantation Did Not Ameliorate the Outcome of Untreated Angioimmunoblastic T-Cell or Follicular T-Helper Lymphoma: Subgroup Analysis of Phase II FIL-PTCL13 Study

Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma

Adding Romidepsin to CHOEP in First Line Treatment of Peripheral T-Cell Lymphomas Does Not Improve the Response Rate: Final Analysis of Phase II PTCL13 Study

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Elderly Patients with Mantle Cell Lymphoma

Comprehensive Minimal Residual Disease (MRD) Analysis of the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial for Younger Patients with Mantle Cell Lymphoma: A Kinetic Model Ensures a More Refined Risk Stratification

LONG-TERM Outcome of a Fondazione Italiana Linfomi Study Comparing Short Rituximab Maintenance Vs Observation after Brief First-LINE R-FND Chemoimmunotherapy Followed By Rituximab Consolidation in Elderly Patients with Advanced Follicular Lymphoma (FL)

Prolonged Survival Of Poor Risk Follicular Lymphoma Patients Following Primary Treatment With Rituximab-Supplemented CHOP Or HDS With Autograft: Long-Term Results Of The Multicenter Randomized GITMO/FIL Trial

Radioimmunotherapy (RIT) with 90 y-Ibritumomab Tiuxetan (Zevalin) in Relapsed or Refractory Aggressive Lymphoma Previously Treated with Rituximab Containing Regimens

Patients with aaIPI 2-3 Diffuse Large B-Cell Lymphoma Achieve 75% Long-Term Survival Following First-Line Rituximab-Supplemented High-Dose Sequential Chemotherapy and Autograft: Final Results of the Prospective Phase II GITIL ( Gruppo Italiano Terapie Innovative nei Linfomi ) Trial.

High-Dose Sequential Chemotherapy (HDS) Followed by Autologous Stem Cell Transplantation (ASCT) in Relapsing/Refractory Hodgkin Lymphoma (HL): Long-Term Results.

Radioimmunotherapy (RIT) with 90 Y-Ibritumomab Tiuxetan (Zevalin) for the Treatment of Relapsed or Resistant Aggressive Diffuse Large B-Cell Lymphoma (DLBCL) Heavily Pretreated with Rituximab + Chemotherapy: A GIMURELL Experience.

Hyperchidam Verona897 Regimen Is Effective in Treatment of Advanced Peripheral T Cell Lymphoma (PTCL): The GITIL Experience in 33 Cases.

Telomere Length Has Prognostic Impact in B-Cell Chronic Lymphocytic Leukemia (B-CLL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only